A More Comfortable Pap Smear
Teal Health creates a system for at-home cervical cancer screening.
Cervical cancer was once the number one cancer killer of women in the U.S.—until the invention of the Pap smear in the 1940s. Over the last seven decades, the mortality rate from cervical cancer has dropped some 60 percent, thanks to better screening. But the procedure itself, which must be performed in a doctor’s office, is uncomfortable at best and inaccessible at worst, and the percentage of women in the U.S. without an up-to-date screening has been increasing—from 14 percent in 2005 to 24 percent in 2019. Kara Egan, one of the cofounders behind Teal Health, wanted to change that. She had a vision for a medical device and health platform that would make it possible for women to collect their own cervical cancer screening sample from the comfort of their own homes. Teal came to IDEO for help designing an applicator and testing experience that would allow users of all body types to safely and accurately collect a sample at home and be inclusive for anyone with a cervix.
97%
of clinical study participants said the Teal Wand was very easy or easy to use.
87%
of participants said they would be more likely to stay current with screening guidelines if Teal Wand was an option.
94%
of participants said they would choose to collect their own sample from home rather than the current standard of care where a clinician collects it in-office.
Cervical cancer is nearly 100 percent preventable when it’s caught early, yet one in four women in the U.S. are not up to date on their screenings.
More than 12,000 people in the U.S. are being diagnosed with cervical cancer every year, and more than 4,000 people die of the disease, which disproportionately impacts Black, Asian, and Hispanic women.
More than half of cervical cancer cases are found in women that are not up-to-date on their screenings.
Creating a better cervical cancer screening experience is an important mission, but also a challenging one. Not only would Teal have to address the regulations that face healthcare device companies, it would also need to build a comprehensive telehealth platform and a physical product—a wand that could easily collect an adequate cell sample, even in the hands of an untrained person.
The first challenge was to create the wand. The device would need to do a lot: It’s impossible for a person to see their own cervix, so the user would have to be able to find the cervix blind, collect the sample themselves, and remove the wand from their bodies without contaminating it on other parts of their anatomy. Because this is something users are likely to do in their bathrooms, where there is no space to lie down, they would need to be able to use the device while standing—and with one hand. From the beginning, the IDEO team set out to design functional, testable prototypes to make sure the idea was viable, and incorporate diverse voices into the research process, including trans, minority, and disabled women.
Because the product is meant for people who aren’t medical professionals, the team worked to design something as simple, intuitive, and unintimidating as possible. They used a 3-D printer to create multiples of every prototype, autoclaves to make sure that the designs they were creating were sterile, and leaned into shapes women are already used to, like the cylindrical shape of a tampon. The wand they created has that same basic form, but with a soft sponge that the user can deploy with the turn of a dial to collect the sample, then close to protect it from contamination on the way out of the body.
With working prototypes in hand, Teal set out to test their efficacy. In an initial study with 220 participants varying in age, race, socioeconomic status, and geography, Teal found that not only were participants able to successfully self-collect samples, they also preferred them over the speculum, the device doctors typically use during a screening. Some 92 percent said if they knew the results were equal they would prefer self-collection, while 87 percent reported they would stay current with screening if Teal Wand was an option. Self-collection took the vast majority under two minutes to complete, and 97% of study participants reported it was very easy or easy to use. The Teal Wand recently received a patent for its unique design.
The IDEO team also worked on the packaging and unboxing experience, which plays an important role in supporting the user through the self-screening process. The team built in thoughtful design cues to give users reassurance that they are using the wand correctly, and to provide the same level of confidence they would have in the results of an in-clinic screening.
In January 2023, Teal raised an $8.8 million seed round from Serena Ventures, Emerson Collective, and Metrodora, and later that year, launched a nationwide clinical trial with leading health organizations including Johns Hopkins University, Yale University, the University of Colorado, Washington University, and others to support FDA submission and approval. It’s an enormous step toward its North Star: catching cervical cancer earlier and saving lives.
Creating a better cervical cancer screening experience is an important mission, but also a challenging one. Not only would Teal have to address the regulations that face healthcare device companies, it would also need to build a comprehensive telehealth platform and a physical product—a wand that could easily collect an adequate cell sample, even in the hands of an untrained person.
The first challenge was to create the wand. The device would need to do a lot: It’s impossible for a person to see their own cervix, so the user would have to be able to find the cervix blind, collect the sample themselves, and remove the wand from their bodies without contaminating it on other parts of their anatomy. Because this is something users are likely to do in their bathrooms, where there is no space to lie down, they would need to be able to use the device while standing—and with one hand. From the beginning, the IDEO team set out to design functional, testable prototypes to make sure the idea was viable, and incorporate diverse voices into the research process, including trans, minority, and disabled women.
Because the product is meant for people who aren’t medical professionals, the team worked to design something as simple, intuitive, and unintimidating as possible. They used a 3-D printer to create multiples of every prototype, autoclaves to make sure that the designs they were creating were sterile, and leaned into shapes women are already used to, like the cylindrical shape of a tampon. The wand they created has that same basic form, but with a soft sponge that the user can deploy with the turn of a dial to collect the sample, then close to protect it from contamination on the way out of the body.
With working prototypes in hand, Teal set out to test their efficacy. In an initial study with 220 participants varying in age, race, socioeconomic status, and geography, Teal found that not only were participants able to successfully self-collect samples, they also preferred them over the speculum, the device doctors typically use during a screening. Some 92 percent said if they knew the results were equal they would prefer self-collection, while 87 percent reported they would stay current with screening if Teal Wand was an option. Self-collection took the vast majority under two minutes to complete, and 97% of study participants reported it was very easy or easy to use. The Teal Wand recently received a patent for its unique design.
The IDEO team also worked on the packaging and unboxing experience, which plays an important role in supporting the user through the self-screening process. The team built in thoughtful design cues to give users reassurance that they are using the wand correctly, and to provide the same level of confidence they would have in the results of an in-clinic screening.
In January 2023, Teal raised an $8.8 million seed round from Serena Ventures, Emerson Collective, and Metrodora, and later that year, launched a nationwide clinical trial with leading health organizations including Johns Hopkins University, Yale University, the University of Colorado, Washington University, and others to support FDA submission and approval. It’s an enormous step toward its North Star: catching cervical cancer earlier and saving lives.
“We were blown away by the thoughtfulness, talent, and diversity of the team and loved every step of this collaborative process. Through our work with IDEO we’ve set the foundation of a culture focused on elevating the woman’s experience in every decision we make.”
